GU Cancers 2025 | CheckMate 214: KIM-1 as a prognostic and predictive biomarker in aRCC
The CheckMate 214 trial (NCT02231749) led to the approval of nivolumab and ipilimumab in advanced renal cell carcinoma (aRCC). Wenxin Xu, MD, Dana-Farber Cancer Institute, Boston, MA, comments on a post-hoc analysis of the trial, which evaluated circulating KIM-1 as a biomarker. Higher baseline KIM-1 levels were linked to poorer outcomes regardless of treatment. A reduction in KIM-1 after one cycle of nivolumab plus ipilimumab correlated with improved progression-free and overall survival. These findings suggest KIM-1 may serve as a minimally invasive biomarker for monitoring immunotherapy response. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
